ArticleFrontiers in medicine2025
Concurrent anti-glomerular basement membrane disease and membranous nephropathy: a case report.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-glomerular basement membrane (GBM) disease is a rapidly progressive glomerulonephritis which, in rare instances, occurs concurrently with membranous nephropathy (MN). We report a case of this patient presented with proteinuria and hematuria, the predominant pathology was crescentic and necrotizing glomerulonephritis with linear staining for immunoglobulin G (IgG) along the glomerular basement membrane (GBM) associated with epi-membranous electron dense immune deposits. The patient tested had significant titers of anti-GBM antibodies (196.27 RU/ml; reference range:0-20 RU/ml), and renal biopsy demonstrated diffuse strongly positive granular staining for phospholipase a2 receptor (PLA2R) along the GBM. The patient received therapy including prednisone, plasmapheresis and CD20 antibodies, which resulted in the clearance of anti-GBM antibodies and eventual recovery of renal function, as evidenced by the return of serum creatinine to normal levels. Earlier diagnosis and timely effective treatments could improve patients' prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.